Filing Flows › Travere Therapeutics (TVTX) › Q2 2026 › vs Q1 2026
Travere Therapeutics (TVTX) Q2 2026 vs Q1 2026 (quarter over quarter)
Travere Therapeutics's revenue rose $42.4M (+33%) from $127M in Q1 2026 to $170M in Q2 2026. The biggest changes: Total net product sales +$36.9M (+30%); License and collaboration revenue +$5.5M (+204%).
Travere Therapeutics, Q2 2026: revenue $170M (+48% year over year), operating margin 2.3%, net loss $34.8M, operating cash flow $58.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| FILSPARI | $141M | $105M | $35.9M | +34% |
| Tiopronin products | $20.3M | $19.3M | $934K | +5% |
| Total net product sales | $161M | $124M | $36.9M | +30% |
| License and collaboration revenue | $8.2M | $2.7M | $5.5M | +204% |
| Revenue | $170M | $127M | $42.4M | +33% |
| Income tax benefit | $204K | $120K | $84K | +70% |
| Net loss | $34.8M | $37.1M | −$2.3M | -6% |
| Costs & expenses | $205M | $164M | $40.2M | +24% |
| Operating costs | $166M | $164M | $1.5M | +0.9% |
| Interest & other, net | $39.0M | $307K | $38.6M | 127× |
| Cost of revenue | $2.2M | $1.9M | $224K | +11% |
| Research & development | $60.3M | $57.1M | $3.2M | +6% |
| SG&A | $96.1M | $80.3M | $15.9M | +20% |
| Other operating costs | $7.1M | $24.8M | −$17.8M | -72% |
| Operating cash sources | $92.9M | −$3.3M | $96.1M | — |
| Depreciation & amortization | $4.2M | $25.2M | −$21.0M | -83% |
| Share-based compensation | $21.8M | $16.1M | $5.6M | +35% |
| Working capital & other | $66.8M | −$44.6M | $111M | — |
| Net loss absorbed | $34.8M | $37.1M | −$2.3M | -6% |
| Operating cash flow | $58.1M | −$40.4M | $98.4M | — |
Questions
How much did Travere Therapeutics's revenue grow quarter over quarter in Q2 2026?
Travere Therapeutics's revenue rose $42.4M (+33%) from $127M in Q1 2026 to $170M in Q2 2026.
What drove Travere Therapeutics's revenue change in Q2 2026?
Total net product sales +$36.9M (+30%); License and collaboration revenue +$5.5M (+204%).